Galinpepimut-S Completes Phase 3 REGAL Interim Analysis in AML
Interim phase 3 results revealed a median survival of at least 13.5 months with galinpepimut-S vs 6 months with standard of care in acute myeloid leukemia.
Related Articles
Fox Chase Cancer Center Welcomes Hanzhi Luo
PHILADELPHIA (January 21, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Hanzhi Luo, PhD, as an Assistant Professor in the…
Pelareorep Plus mFOLFIRINOX ± Atezolizumab Shows Acceptable Safety in Metastatic PDAC
Pelareorep plus modified FOLFIRINOX with or without atezolizumab showed acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.
Beyond the $500B Stargate Project: The frontier of AI in oncology beckons – The Cancer Letter
On Jan. 21, President Donald Trump announced the launch of the Stargate Project, a $500 billion artificial intelligence infrastructure project designed to revolutionize healthcare. To…
FDA Supports Registrational Strategy for ELI-002 in KRAS-Driven Cancers
Pending phase 3 trial results, a biologics license application will be submitted for the KRAS-targeting cancer vaccine ELI-002.
RWD company documents baseline trends in women’s cancers before Trump’s policy changes – The Cancer Letter
The U.S. Supreme Court’s June 2022 decision to overturn Roe v. Wade has implications that reach far beyond access to reproductive health care services in…
Sisters Take Bold Step Together Against BRCA Mutation
Women with BRCA mutations have a more than 60% increased risk for breast cancer and up to 30% increased risk for ovarian cancer
From clinician scientist to nonprofit CEO – The Cancer Letter
I was a practicing pediatric hematologist oncologist and researcher for 21 years. As a doctor, it was a tremendous privilege to be invited into the lives…
NIPS Boosts Overall Survival Over PS in Gastric Cancer With Peritoneal Metastasis
Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.
Feng’s team advanced the understanding of biomarkers in prostate cancer – The Cancer Letter
Felix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48. This article is republished with permission by NRG Oncology.…
Member Highlight: Lahey Hospital & Medical Center | SWOG
Among our main member, non-LAPS institutions, Lahey Hospital and Medical Center, based north of Boston, in Burlington, Massachusetts, is a great choice to profile. It’s a…
